Thank you for your interest

Listen to the Podcast below, or view a Transcript of the Podcast here

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche.

Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at www.discoveryontarget.com/dot/archives